JACCRO CC-11 study
Ontology highlight
ABSTRACT: Interventions: FOLFOXIRI+/-bevacizumab (To 12 courses), 5-FU+Levofolinate+/-bevacizumab (From 13 courses) given on day 1 every 2 weeks, until disease progression or unmanageable toxicity.
bevacizumab 5mg/kg/bi-weekly
Irinotecan 150mg/m2/bi-weekly
Oxaliplatin 85mg/m2/bi-weekly
Levofolinate 200mg/m2/bi-weekly
5-FU 2400mg/m2/bi-weekly
Primary outcome(s): Response Rate
Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
DISEASE(S): Colorectal Cancer
PROVIDER: 2613998 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA